Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Developments towards antiviral therapies against enterovirus 71

Kan X. Wu, Mary M.-L. Ng and Justin J.H. Chu

Department of Microbiology, Yong Loo Lin School of Medicine, National University Health System, 5 Science Drive 2, National University of Singapore, Singapore

Enterovirus 71 (EV71) has emerged as a clinically important neurotropic virus that can cause acute flaccid paralysis and encephalitis, leading to cardiopulmonary failure and death. Recurring outbreaks of EV71 have been reported in several countries. The current lack of approved anti-EV71 therapy has prompted intense research into antiviral development. Several strategies – ranging from target-based chemical design to compound library screenings – have been employed, while others revisited compound series generated from antiviral developments against poliovirus and human rhinoviruses. These efforts have given rise to a diversity of antiviral candidates that include small molecules and non-conventional nucleic-acid-based strategies. This review aims to highlight candidates with potential for further clinical development based on their putative modes of action.

Enterovirus 71 (EV71) is described as one of the human enterovirus A species under the genus Enterovirus in the Picornaviridae family of viruses, which includes poliovirus [1]. While efforts to eradicate poliovirus through vaccination programs have limited the number of polio-endemic countries to just four (Afghanistan, India, Nigeria and Pakistan) [2], EV71 has emerged as an important non-polio neurotropic enterovirus.

EV71 was first isolated from patients with central nervous system diseases in California between 1969 and 1974 [3]. The same authors also described the EV71 prototype strain, BrCr, isolated from a two-month-old patient who presented with aseptic meningitis. Since then, EV71 outbreaks have been reported in several countries beyond North America, including Taiwan, Australia, Malaysia and Singapore [4]. These outbreaks have mainly involved young children, with most cases displaying mild, self-limiting hand, foot and mouth disease; however, EV71 outbreaks have also been associated with a variety of severe neurological complications that can deteriorate rapidly to involve cardiopulmonary failure with high mortality rates. Transmission of EV71 can occur rapidly via the fecal–oral and droplet and/or aerosol routes. During the largest EV71 outbreak to date, in Taiwan in 1998, more than 100,000 children were affected, with 405 severe cases involving neurological or cardiopulmonary complications, of which 78 were fatal [5].

The spectrum of EV71-associated neurological diseases includes aseptic meningitis, brain stem encephalitis and poliomyelitis-like acute flaccid paralysis. Like poliomyelitis, severe EV71 infections can result in permanent neurological damage. In a long-term study of children who survived neurologically involved EV71 infections during the 1998 outbreak in Taiwan, patients who had a more severe infection (involving both neurological and cardiopulmonary complications) displayed signs of neurologic sequelae, impaired neurodevelopment and impaired cognitive functions [6].

There is currently no effective vaccine or antiviral against EV71. Treatments for acute EV71 infections with neurological manifestations mainly aim to alleviate symptoms. Mechanical cardiopulmonary support systems and the administration of milrinone, a positive inotropic agent, have been used to prevent cardiopulmonary failure and thus improve the clinical outcome of patients [7]. The lack of antiviral treatment options against EV71 remains a worrying situation, however, because EV71 has been found to circulate endemically with peak activity in warmer seasons (e.g. summer to fall) [8]. Considering the propensity of EV71 to cause severe neurological diseases in children, there is a need to develop effective antiviral treatment options to prevent or reduce EV71-related deaths and long-term neuropathy in the next EV71 global outbreak.

In this review, we focus on documenting recent developments towards an antiviral for EV71 infections. Previous reviews have
covered the development of antivirals targeting picornaviruses or enteroviruses in general [9–15]; however, with the exception of poliovirus, EV71 has distinguished itself from other enteroviruses in terms of circulation and severity of associated diseases. In contrast to poliovirus, against which highly effective vaccines are available, the global population remains largely unprotected against EV71. Our review, therefore, highlights promising anti-EV71 strategies and their putative modes of inhibition.

**General virology of picornaviruses**

An understanding of the molecular mechanisms of viral infection and replication can enable the identification of potential antiviral targets. Although the exact mechanisms for EV71 replication have not been elucidated, picornaviruses generally share a highly similar virus architecture and mode of replication. Picornaviruses are non-enveloped viruses of ~30 nm in diameter with an icosahedral capsid made up of 60 protomers, each of which is, in turn, made up of four structural proteins: VP1, VP2, VP3 and VP4. The picornavirus genome is encoded as a single-stranded, positive-sense RNA of 7500–8000 bases that consists of an open reading frame flanked by 5’ and 3’ untranslated regions (UTRs).

Upon virus attachment and entry into the host cell, an uncapping event occurs to release the RNA genome into the cell. Covalently attached to the 5’ end is a viral protein, VPg (3B), which is cleaved by a cellular enzyme during early infection, whereas the 3’ end has a poly(A) tract. The 5’ and 3’ UTRs are highly structured regions that interact with a variety of viral and host proteins in translation and RNA synthesis events.

Cap-independent translation of the viral RNA takes place through the recruitment of host replication machinery at the internal ribosome entry site located in the 5’ UTR of the viral RNA. The viral polyprotein can be divided into three precursor molecules (P1, P2 and P3) (Fig. 1). P1 contains all the viral capsid proteins, VP1–4, and P2 and P3 carry the viral non-structural proteins. Functional viral proteins and precursor proteins are produced upon maturation cleavage of the polyprotein by the virus-encoded proteases 2Apro and 3Cpro. Negative RNA intermediates of

![Graphical overview of picornavirus replication](image-url)
the viral genome are also generated to serve as templates for the replication of positive-sense RNA viral genomes. These events typically take place in virus-induced membrane complexes within host cells. Progeny virions are then self-assembled from the synthesized viral proteins and RNA genomes before their subsequent release from the host cell [16] (Fig. 1).

**Inhibitors of virus attachment, entry and uncoating EV71 receptors**

Receptor binding is an essential event in virus infection. The ability to recognize and bind specific receptors typically determines the host range and tissue tropism of viruses. The recent characterizations of EV71 receptors have opened the door to the development of antiviral strategies targeting EV71 entry into host cells.

At least three cellular receptors for EV71 have been reported to date. Human scavenger receptor class B, member 2 (SCARB2) was described as a receptor for EV71 strains from all three genogroups (A, B and C) [17]. SCARB2 is a type III double-transmembrane protein primarily located in endosomes, although surface expression of SCARB2 has also been demonstrated [17]. The second EV71 receptor, human P-selectin glycoprotein ligand-1 (PSGL-1/CD162), is a sialomucin membrane protein expressed mainly in leukocytes, including dendritic cells and macrophages [18]. PSGL-1 was postulated to facilitate the viremic phase of EV71 by enabling replication in circulating leukocytes [19]. Using monoclonal antibodies targeting different parts of PSGL-1, the authors identified the N-terminal region as a crucial interaction site for EV71. The sialic acid residue of PSGL-1 might also be important for EV71 interaction. In the study by Yang et et al. [20], sialidase removal of sialic acid residues from plasma membrane proteins was able to protect EV71-susceptible DLD-1 intestinal cells from infection. In another study, EV71 was found to infect immature dendritic cells via DC-SIGN. Infection was reduced by up to 50% when anti-DC-SIGN antibody was used to block DC-SIGN [21].

The potential for the development of antiviral strategies targeting EV71 receptor binding was demonstrated in all these studies. Anti-SCARB2 antibodies and soluble SCARB2–Fc conjugates were able to inhibit EV71 infection in a dose-dependent manner [17]. Likewise, soluble PSGL-1, monoclonal antibodies targeting the N-terminal of PSGL-1 [19] and sialylated glycans purified from human milk [20] displayed dose-dependent inhibition of EV71 in co-infection and pretreatment experiments. Unfortunately, these were unable to inhibit EV71 infection completely at the highest concentrations tested, suggesting the involvement of multiple receptors during EV71 infection. This can be addressed in the future by the combined administration of inhibitors targeting different EV71 receptors. The potential discovery of more EV71 receptors in the future (in particular, neural-specific receptors) might eventually lead to the development of effective receptor inhibitors that can prevent EV71-induced neuropathology.

**Viral capsid-binding molecules**

The hydrophobic pocket within the viral protein, VP1, is a well-known target for antiviral design because its occupancy by suitable compounds will stabilize the virus capsid and prevent uncoating of virus for RNA release [22]. Some of the more prominent series of capsid-binding compounds include the WIN series from Sterling-Winthrop (e.g. Pleconaril) [23], the SCH series from Schering-Plough (e.g. SCH 48973) [24] and R 77975-related compounds from the Janssen Research Foundation (e.g. Pirodavir) [25]. Although antiviral activity was claimed for a broad spectrum of picornaviruses, EV71 was notably absent from the list of picornaviruses tested in these studies. The characteristics and clinical developments of picornavirus capsid-binding molecules are detailed in several comprehensive reviews [9,13,15]. After the 1998 Taiwan outbreak of EV71, Pleconaril was tested against EV71 but failed to prevent virus-induced cytopathic effects in cell cultures [26]. In view of the emergence of EV71 as a clinically important picornavirus, there is a need to re-evaluate more of these compounds against EV71.

**Pyridyl imidazolidiones**

Using WIN compounds as templates, a series of imidazolidone derivatives were designed through computer modeling, synthesized and evaluated for their ability to inhibit EV71-induced cytopathic effects in rhabdomyosarcoma (RD) cells. Several lead molecules with strong inhibition against all three genogroups of EV71 (EC50 = 2.13–4.67 μM) and low cytotoxicity (CC50 > 25 μM) were discovered. A series of publications by the same group later documented the various chemical modifications that improved antiviral activity, including substitutions on the phenoxyl group (BPROZ-194, EC50 = 1.55 μM), oxime ether group addition (BPROZ-101, EC50 = 0.0012 μM) and methyl group addition (BPROZ-033, EC50 = 0.009 μM) [27]. These compounds were evaluated for anti-EV71 activity in a murine model with promising results, although a current lack of funding is impeding progress to clinical trials (S.R. Shih, pers. commun.).

**Pyridanzinyl oxime ethers**

Oxime-ether derivatives of Pirodavir displayed improved metabolic stability and antiviral activity against a greater spectrum of picornaviruses relative to Pirodavir [28]. Most notably, one of these compounds, BTA39, inhibited EV71 with an EC50 of 0.001 μM and a reported CC50 ≥ 4.588 μM [29].

**Lactoferrin**

Bovine lactoferrin and human lactoferrin were found to inhibit EV71 infection in RD cells during early stages of infection at a mean EC50 of 10.5–24.5 μg/ml and 103.3–185.0 μg/ml, respectively [30]. Bovine lactoferrin delayed EV71-induced paralysis and death for up to two weeks post-infection in 17-day-old mice when co-infected with EV71, and interaction assays using conjugated antibodies demonstrated direct binding of lactoferrin with VP1 and cell surfaces [31]. These suggested lactoferrin’s role in preventing virus attachment by blocking cellular receptors and/or receptor-interaction sites on EV71. The exact antiviral mechanism of lactoferrin remains to be determined; however, its potency as an early inhibitor of EV71 has led to the authors of these studies to propose investigating the ingestion of milk as a prophylaxis.

**NF449**

Suramin, a polysulfonate, was shown to be an effective inhibitor of HIV replication in infected patients. Polysulfonates are known to be multi-targeting inhibitors of HIV, with viral targets including reverse transcriptase and the viral envelope gp120 glycoprotein [32]. A suramin analog, NF449, 4,4′,4″-(carbonylbis(imino-
Several peptide aldehydes were designed to irreversibly inhibit human rhinovirus (HRV) 3Cpro by forming covalent adducts (reviewed in Ref. [9]). One of these compounds, rupintrivir (AG-7088, Pfizer) reached phase II clinical trials but further studies were ceased after it displayed poor efficacy in natural infection cases of HRV [44].

Kuo et al. [45] developed a series of compounds based on rupintrivir and tested against EV71 3Cpro in vitro. A compound, 10b, was identified as a potent inhibitor with EC50 of 0.018 μM while showing no toxicity (CC50 > 25 μM). Further studies are needed to evaluate the compound’s efficacy in vivo. More recently, rupintrivir was shown to inhibit EV71 with an EC50 of 0.8 μM using a real-time, cell-based fluorescence resonance energy transfer assay and plaque reduction assay [46]. Compound 1, an orally bioavailable 3Cpro inhibitor developed in parallel with rupintrivir, also showed in vitro antiviral properties against several other human enteroviruses and should also be evaluated for anti-EV71 properties [47].

**Inhibitors of protein 2C**

The highly conserved picornavirus protein 2C is a multifunctional protein that possesses nucleoside triphosphatase activity [48] and was shown to be involved in the synthesis of the viral negative-strand RNA [49] and encapsidation of progeny virions in poliovirus [50]. EV71 2C protein was reported to recruit host-encoded reticulon 3 in forming replication complexes [51].

**Metrifudil and N6-benzyladenosine**

Metrifudil, N-(2-methylphenyl)methyl-adenosine and N6-benzyladenosine were identified as inhibitors of EV71 in the same screen as NF449 (inhibitors of virus attachment, entry and uncoating). Reported EC50 of 1.3 μM (metrifudil) and 0.10 μM (N6-benzyladenosine) were derived against EV71 pseudovirus (structural genes replaced by firefly luciferase gene). Metrifudil and N6-benzyladenosine, both adenosine receptor agonists, also showed low cytotoxicity with CC50 of >50 μM and 3300 μM, respectively [33]. The authors managed to isolate drug-resistant EV71 with mutations in 2C proteins after three passages, thus suggesting non-conserved regions in 2C as probable targets of the compounds.

**Inhibitors of protein 3A**

Picornavirus 3A protein is an essential, multifunctional protein that has been shown to modulate the host cell’s intracellular membrane transport [52]. Protein 3A functions primarily in its precursor form, 3AB, which has RNA-binding properties and is known to stimulate the cleavage of 3CDpro and the activity of 3D RNA polymerase 3Dpol [53,54].

**Enviroxime and its structural analogs**

Enviroxime is a benzimidazole derivative that inhibits rhinoviruses and poliovirus in vitro by targeting protein 3A [55,56]. Recently, enviroxime was reported to have strong antiviral effects against EV71 with an EC50 of 0.15 μM [57]. Enviroxime, however, was unable to show significant clinical effect (p > 0.05) against HRV9, with poor bioavailability and gastrointestinal side-effects observed in trial subjects [58]. Vinylacetylene analogs of enviroxime were reported to display better oral bioavailability while retaining protein 3A targeting antiviral activity against poliovirus [59] and, therefore, should be evaluated for anti-EV71 activity (Table 1).

5,1,3-benzenetriylbis(carbonylimino))tetraakis-benzen-1,3-disulfonic acid, was identified as an early inhibitor of EV71 infection (virus uncoating or host receptor binding) with an EC50 of 6.7 μM and CC50 of >1000 μM in a screen for anti-EV71 compounds in the LOPAC1280 drug library (Sigma–Aldrich) [33]. NF449-resistant NF449 of NF449.

Inhibitors of protein synthesis

Translation of the viral RNA is the next key step of virus replication. Because the virus essentially uses cellular machinery for protein translation, it is important to develop antiviral strategies that inhibit viral protein synthesis without affecting host cell translation events. Currently, there are no reports of viral-specific small-molecule inhibitors of protein synthesis with activity against EV71. Amantadine was found to inhibit cap-independent translation initiated by the EV71 internal ribosome entry site in a bicistronic reporter system, although direct antiviral activity was not verified [34]. A more promising but non-conventional antiviral approach targeting viral RNA translation might be RNA interference (RNAi).

RNA interference

The potential of nucleic-acid-based therapy can be seen from the FDA approval of fomivirsen (Vitravene) for use against cytomegalovirus retinitis [35]. Many RNAi-based antiviral therapeutics are currently undergoing various phases of clinical trials against viruses such as HIV-1, respiratory syncytial virus and hepatitis C virus [36].

Several highly conserved sequences have been identified as targets for RNAi in the EV71 genome. Small interfering RNA (siRNA) and plasmid-encoded short hairpin RNA (shRNA) were found to effectively block replication of EV71 when targeted against 3’ UTR [37] or regions encoding the structural proteins (e.g. VP1 and VP2) [38] and non-structural proteins (e.g. 2C, 3C and 3D) [37,39]. Two of these studies reported the greatest inhibitory effects in targeting the viral RNA polymerase 3D [39,40]. siRNA and plasmid-encoded shRNA targeting 3D were able to prevent EV71-induced paralysis, weight loss and death in suckling mice when delivered via the oral or intraperitoneal route [40]. The authors also observed similar antiviral effects for nucleotides delivered with or without a lipid carrier. These promising preclinical results should be followed up with clinical trials for RNA-based anti-EV71 therapeutics.
TABLE 1

Anti-EV71 activity of select compounds

| Inhibitor                | Structure | EC<sub>50</sub> (μM) | CC<sub>50</sub> (μM) | Current status (reference) |
|--------------------------|-----------|-----------------------|----------------------|---------------------------|
| **Capsid-binding**       |           |                       |                      |                           |
| BPROZ-194                | ![BPROZ-194](image) | 1.552                 | >50                  | In vitro [27]             |
| BPROZ-101                | ![BPROZ-101](image) | 0.0012                | >50                  | In vitro [27]             |
| BPROZ-033                | ![BPROZ-033](image) | 0.0088                | >50                  | In vitro [27]             |
| BTA39                    | ![BTA39](image) | 0.001                 | ≥4.588               | In vitro [29]             |
| Bovine lactoferrin       | N/A       |                       |                      |                           |
| NF449                    | ![NF449](image) | 10.5*                 | N/R                  | In vivo; mice [31]        |
|                          |           | 6.7                   | >1000                | In vitro [33]             |
| **Translation-inhibition**|           |                       |                      |                           |
| siRNA (3D)               | N/A       | < 5nmol<sup>+</sup>   | N/R                  | In vivo; mice [40]        |
| shRNA (psi-3D)           | N/A       | <25 μg<sup>+</sup>   | N/R                  | In vivo; mice [40]        |
| 3C<sup>pro</sup> inhibitor | ![3C<sup>pro</sup> inhibitor](image) | 0.018                 | >25                  | In vitro [45]             |

<sup>+</sup> Na<sup>+</sup>
| Inhibitor       | Structure | $\text{EC}_{50}$ ($\mu$M) | $\text{CC}_{50}$ ($\mu$M) | Current status (reference) |
|-----------------|-----------|---------------------------|---------------------------|---------------------------|
| Rupintrivir     | ![Rupintrivir Structure](image1) | 0.8                        | N/R                       | In vitro [46]             |
| 2C inhibitors   |           |                           |                           |                           |
| Metrifudil      | ![Metrifudil Structure](image2) | 1.3                        | >50                       | In vitro [33]             |
| N$^4$-benzyladenosine | ![N$^4$-benzyladenosine Structure](image3) | 0.10                       | 3300                      | In vitro [33]             |
| 3A inhibitors   |           |                           |                           |                           |
| Enviroxime      | ![Enviroxime Structure](image4) | 0.15                       | N/R                       | In vitro [57]             |
| GW5074          | ![GW5074 Structure](image5) | 2.0                        | 170                       | In vitro [33]             |
| 3Dpol inhibitor |           |                           |                           |                           |
| DTnP22          | ![DTnP22 Structure](image6) | 0.15                       | >100                      | In vitro [64]             |
| Inhibitor          | Structure      | EC<sub>50</sub> (µM) | CC<sub>50</sub> (µM) | Current status (reference) |
|--------------------|----------------|-----------------------|----------------------|---------------------------|
| Aurintricarboxylic acid | ![Structure](image1) | 2.9                   | 211                  | In vitro [65]              |
| Nucleoside analog  |                |                       |                      |                           |
| Ribavirin          | ![Structure](image2) | 65 µg/ml              | >200 µg/ml           | In vivo; mice [69]         |
| Antioxidant        |                |                       |                      |                           |
| Epigallocatechin gallate | ![Structure](image3) | <10                   | N/R                  | In vitro [70]             |
| Interferon inducer |                |                       |                      |                           |
| Aloe-emodin        | ![Structure](image4) | 0.14 µg/ml            | 2632 µg/ml           | In vitro [73]             |
| Unknown mechanism  |                |                       |                      |                           |
| Chloroquine        | ![Structure](image5) | <1.2 mM<sup>b</sup>   | N/R                  | In vitro [74]             |
| Allophycocyanin    | N/A            | 0.101                 | 1.521                | In vitro [77]             |
| Raoulic acid       | ![Structure](image6) | 0.1 µg/ml             | 65.86 µg/ml          | In vitro [78]             |
GW5074
Other scholars have reported several functional analogs of enviroxime that also target protein 3A. GW5074, 3-(3,5-dibromo-4-hydroxybenzylidine-5-ido-1,3-dihydro-indol-2-one), is a Raf-1 inhibitor identified as an inhibitor of EV71 in the same drug library screen described previously for metrifudil (inhibitors of 2C protein). GW5074 was found to have a CC50 of 170 μM and inhibited EV71 pseudovirus at an EC50 of 2.0 μM. Post-infection addition of 50 μM of GW5074 also showed 102 to 103-fold of inhibition [33]. The target of GW5074, identified in a later study, was found to be the same region targeted by enviroxime in the protein 3A [60]. GW5074 is currently being evaluated for in vivo anti-EV71 activity in a murine model (M. Arita, pers. commun.).

Inhibitor of 3D RNA polymerase
The picornavirus 3D RNA polymerase is involved in several crucial replication events besides the incorporation of nucleotides during the synthesis of negative and positive viral RNA strands. Studies have shown that 3Dpol is responsible for the uridylation of VPg, which confers the priming function of VPg during RNA replication [61]. Viral protein 3CD, the precursor form of 3Dpol, is also involved in polyprotein processing [62] and promotes RNA synthesis by binding to the 5’ cloverleaf structure on the viral RNA [63].

DTriP-22
DTriP-22 is a synthetic compound from a series of piperazine-containing, pyrazolo[3,4-d]pyrimidine derivatives that was identified as a novel class of compounds with anti-EV71 activities. This compound was evaluated to have an EC50 of 0.15–0.98 μM against strains from all genotypes of EV71 and a CC50 greater than 100 μM. It was found to suppress the synthesis of both positive and negative strands of viral RNA during EV71 infection, and subsequent analyses of resistant viruses identified DTriP-22’s target as the RNA polymerase of EV71, 3Dpol [64].

Aurintricarboxylic acid
Aurintricarboxylic acid (ATA) is a polyanionic compound with broad-spectrum antiviral activity reported against a variety of viruses (e.g. HIV and severe acute respiratory syndrome coronavirus). It was recently reported to be a potent EV71 inhibitor with a plaque reduction assay derived EC50 of 2.9 μM, while displaying low cytotoxicity in African green monkey kidney (Vero) cells with a CC50 of 211 μM [65]. The authors managed to rule out ATA targeting of viral adsorption, viral RNA translation and the viral proteases (2Apro and 3Cpro) while observing ATA inhibition of RNA elongation by EV71 3Dpol.

Nucleoside analog
Ribavirin
Ribavirin is a broad-spectrum antiviral that has been used in treating hepatitis C virus infections (in combination with interferon-α) [66] and severe respiratory syncytial virus infections [67]. Studies have shown that the main antiviral mechanism of ribavirin is through lethal mutagenesis of viruses during RNA replication events [68]. Ribavirin was found to inhibit EV71 in RD cells with EC50 of 65 μg/ml (266 μM) while preventing EV71-induced paralysis and death in mice [69]. With continued progress in antiviral development for EV71, ribavirin might prove to be clinically useful for EV71 infections in the future, when used at lower concentrations in combination with other antivirals.

Modulators of host cell environment
Antioxidant
Epigallocatechin gallate. Polyphenolic compounds isolated from green tea leaves (Camellia sinensis) were tested for their antiviral properties against EV71. Epigallocatechin gallate (EGCG) was found to be the most potent of these compounds with post-infection addition of 10 μM of EGCG resulting in 54% reduction in plaque formation, while EV71-induced cytopathic effects were reduced by two-fold and viral RNA levels were significantly decreased (p < 0.05, treated vs control). EGCG’s potency as an anti-EV71 agent among the polyphenols tested correlated with its high antioxidative capacity [70]. EV71 infection was observed to result in increased oxidative stress, while cells deficient in glucose-6-phosphate dehydrogenase supported more efficient EV71 replication [71]. The association between cellular redox status and EV71 replication led the authors to suggest EGCG inhibits EV71 replication by modulating oxidative stress. However, it remains unclear whether this association represents a direct causal relationship between EGCG and EV71 inhibition.

Type I interferons
The induction of Type I interferons (IFNs; e.g. interferon-α/β) is an early, non-specific host immune response to viral infections that

| Inhibitor          | Structure | EC50 (μM) | CC50 (μM) | Current status (reference) |
|--------------------|-----------|-----------|-----------|---------------------------|
| Ursolic acid       |           | 0.5 μg/ml | 100.5 μg/ml | In vitro [79]             |

EC50, 50% effective concentration; CC50, 50% cytotoxic concentration; N/A, not applicable; N/R, not reported.

a 50% reduction of EV71 RNA from extracted intestinal cells (mice).

b 104-fold inhibition of EV71 RNA synthesis.
can lead to the induction of antiviral mechanisms. Injection of 10 μg of polyriboinosinic-polyriboytidic acid [poly(I:C)], a potent IFN inducer, into mice 12 hours before EV71 inoculation resulted in increased serum levels of IFN-α, improved survival rate and significantly decreased tissue viral load (p < 0.05, treated vs control) and mortality [72].

Aloe-emodin. Aloe-emodin, a plant-derived anthraquinone derivative, was able to induce a 2.5-fold increase in IFN-α expression in human medullablastoma (TE-671) cells while showing low toxicity to both human promonocyte (HL-60) and TE-671 cell lines (CC₅₀ of 2632 μg/ml and 2881 μg/ml, respectively). Pretreatment of cells from both cell lines with aloe-emodin resulted in lowered plaque formation when infected with EV71 (EC₅₀ of 0.14 μg/ml and 0.52 μg/ml, respectively) [73]. The resulting high therapeutic index (CC₅₀/EC₅₀) values for aloe-emodin suggest its therapeutic potential as an anti-EV71 compound.

Compounds with unverified targets and modes of action

Synthetic compound

Chloroquine

Chloroquine was used as an inhibitor of virus uncoating in a study of EV71-induced apoptosis whereby the experiments were not designed to investigate chloroquine’s anti-EV71 characteristics. Nonetheless, treatment with 1.2 ms of chloroquine resulted in a 10⁴-fold reduction of EV71 RNA synthesis [74].

The antimalarial drug chloroquine has gained interest as a potent antiviral drug, with studies showing its antiviral activities against diverse viruses such as severe acute respiratory syndrome coronavirus [75] and HIV [76]. Investigations into the inhibitory mechanisms of chloroquine on these viruses showed a variety of targets and processes involved. Given the varied antiviral pathways of chloroquine, the authors’ claim of uncoating inhibition has to be verified with further experiments. However, the experience from the use of chloroquine in malaria treatment and its wide availability add to the appeal of investigating its anti-EV71 potential.

Natural compounds

Allophycocyanin. Allophycocyanin is a red fluorescent protein purified from the marine algae Spirulina platensis that has been found to prevent EV71-induced apoptosis, delay viral RNA synthesis and reduce plaque formation at an EC₅₀ of 0.1 μM and CC₅₀ of 1.52 μM in post-infection experiments on Vero cells [77]. The specific targets for inhibition by allophycocyanin are currently unknown.

Raoulia acid. Raoulic acid was purified from whole-plant extract of a New Zealand plant, Raoulia australis, and tested for antiviral activity against a wide range of viruses. It has a CC₅₀ of 65.86 μg/ml in Vero cells and was able to inhibit EV71 with an EC₅₀ of less than 0.1 μg/ml, giving it a therapeutic index of greater than 656.8 [78]. Drug treatment was performed post-infection, and the targets for inhibition were not investigated in the study.

Ursolic acid. Ursolic acid is a triterpenoid purified from the water extract of Ocimum basilicum, a herb commonly used in traditional Chinese medicine. Ursolic acid showed low cytotoxicity against Hep G2 (hepatoblastoma-derived) cells (CC₅₀ = 100.5 μg/ml) and inhibited EV71-induced cytopathic effects (EC₅₀ = 0.5 μg/ml) [79]. Time-of-addition studies revealed only post-infection inhibition of EV71 for the lower doses of ursolic acid tested (0.125 and 0.25 μg/ml), although the exact mechanisms of inhibition remain unclear.

Concluding remarks and future prospects

Because most of the antiviral agents of EV71 in the literature are only in the preliminary stages of development (i.e. in vitro studies), promising candidates were selected based on their antiviral potencies and cytotoxicity profiles. Among the compounds mentioned in this review, those that are approved for clinical use in other diseases (e.g. chloroquine) or are generally non-toxic (e.g. lactoferrin) are attractive candidates for evaluation in vivo and in clinical trials.

Earlier efforts in the development of antiviral agents against HRV and poliovirus have yielded compound series with antipicornaviral activities. Research into these series, however, seems to have ceased with the highly successful implementation of oral polio vaccine. These compounds might still prove useful as anti-EV71 agents or lead molecules for designing effective anti-EV71 agents, as exemplified by the development of anti-EV71 capsid binders, and should be evaluated against current EV71 strains. In fact, the extensive pharmacokinetic characterizations in various stages of clinical trials for compounds such as Pleconaril (capsid binder), rupintrivir (3C₅₀ inhibitor) and enviroxime (3A inhibitor) can serve to inform future developments of anti-EV71 agents.

The mechanisms behind the neuropathogenesis of EV71 infection are currently unknown. Several theories have been proposed, including host immune-mediated inflammation of the central nervous system (CNS) and neural apoptotic cell death as EV71 infection spreads to the CNS [80]. A murine study reported retrograde axonal transport to be the major transmission route for EV71 neuroinvasion, in contrast to a hematogenous transmission with virus crossing the blood–brain barrier. Skeletal muscle was found to serve as an important site for viral replication and entry into the CNS via peripheral nerves innervating the infected site [81]. In fatal EV71 infection cases, patients usually present with three to five days of fever, headache, oral ulcers and vesicular rashes on hand, foot or buttocks that test positive for EV71 before rapid deterioration to severe disease [82]. The lag time between primary infection to severe neural disease might prove to be an important window of opportunity for antiviral intervention. Although the neuropathogenesis of EV71 would argue for a systemic antiviral that can cross the blood–brain barrier, other routes of administration might also prove to be useful in preventing EV71 neuroinvasion and transmission by inhibiting EV71 replication at other sites of infection (e.g. skeletal muscle, gastrointestinal lining and vesicular rashes on the skin).

With no antiviral or prophylactic available for severe EV71 infections, all available antiviral options should be considered pending future progress in our understanding of disease progression in EV71 infection and future reports on the in vivo efficacies and pharmacokinetics of antiviral candidates. An effective antiviral is an essential tool in nullifying the growing threat of EV71 as a neurotoxic virus. Even as the search for an EV71 vaccine continues, development of antiviral agents remains pertinent, as seen in the case of poliovirus, in which the lack of antiviral options is preventing a complete eradication of polio [56].
66 de Ledinghen, V. et al. (2002) Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J. Hepatol. 36, 672–680
67 Wyde, P.R. (1998) Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39, 63–79
68 Crotty, S. and Andino, R. (2002) Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect. 4, 1301–1307
69 Li, Z.H. et al. (2008) Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J. Infect. Dis. 197, 854–857
70 Ho, H.Y. et al. (2009) Antiviral effect of epigallocatechin gallate on enterovirus 71. J. Agric. Food Chem. 57, 6140–6147
71 Ho, H.Y. et al. (2008) Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J. Gen. Virol. 89, 2080–2089
72 Liu, M.L. et al. (2005) Type I interferons protect mice against enterovirus 71 infection. J. Gen. Virol. 86, 3263–3269
73 Lin, C.W. et al. (2008) Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int. J. Antimicrob. Agents 32, 355–359
74 Shih, S.B. et al. (2008) Viral protein synthesis is required for enterovirus 71 to induce apoptosis in human glioblastoma cells. J. Neurovirol. 14, 53–61
75 Vincent, M.J. et al. (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69
76 Savarino, A. et al. (2004) Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J. Acquir. Immune Defic. Syndr. 35, 223–232
77 Shih, S.R. et al. (2003) Inhibition of enterovirus 71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J. Med. Virol. 70, 119–125
78 Choi, H.J. et al. (2009) Antiviral activity of raoulic acid from Raoulia australis against picornaviruses. Phytomedicine 16, 35–39
79 Chiang, L.C. et al. (2005) Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin. Exp. Pharmacol. Physiol. 32, 811–816
80 Weng, K.F. et al. (2010) Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 12, 505–510
81 Chen, C.S. et al. (2007) Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J. Virol. 81, 8996–9003
82 Chan, K.P. et al. (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg. Infect. Dis. 9, 78–85